Autoimmune Diseases
297
81
87
116
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
22 trials with published results (7%)
Research Maturity
116 completed trials (39% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.7%
8 terminated out of 297 trials
93.5%
+7.0% vs benchmark
6%
17 trials in Phase 3/4
19%
22 of 116 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 116 completed trials
Clinical Trials (297)
Deciphering the Genetic Architecture of Autoimmune Diseases
Biomarkers in Autoimmune Disease of Nervous System
A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
Immuno-Oncology Database and Bioregistry
FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Study of STIM1 Membrane Expression
Clinical Performance of the New Plasma Filter PX2 in TPE Treatments
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
CAR-T Cells Targeting Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
Disease-Modifying Treatments for Myasthenia Gravis
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases